A large portion of innovative companies are in discovery, preclinical or early clinical stages with therapeutics aimed at oncology and infectious diseases. There is promising growth in overall biologics therapies, driven by increased funding and growing patient demand.
However, emerging innovators do not possess the necessary infrastructure in-house and are underserved by current manufacturing landscape that is not customized for early phase pipeline needs.
Partnering with a single CDMO can increase speed to market, ensure production capacity and avoid costly and time-consuming tech transfers.
Download our white paper for insights on:
- How our integrated analytical, process development and manufacturing teams can streamline drug development
- How we balance the science of discovery with the engineering mindset for manufacturing
- How we evolve with your needs with our end-to-end CDMO support from discovery to GMP manufacturing
More from Curia
Often, aggressive timelines are imposed on development projects with the aim of getting to First-in-Human trials as soon as possible. However, formulation development can be met with many challenges as biologics are often sensitive molecules with a v...